enGene Reports Full Year 2025 Financial Results and Provides Business Update
Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol enGene se
(Financial Post, 2025-12-22T21:11:40Z)